Phase i task area b -21-0013 - base
Ended Awarded Last action
- Contract number
- 75N93022F00057
- Awardee
-
Dynport Vaccine Company LLC UEI LXNEGTYDR755
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,167,891
Award facts
- Contract value 100% obligated
- $5,167,891.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $11,856 | |
| Supplemental Agreement for work within scope | $313,862 | |
| Supplemental Agreement for work within scope | $22,704 | |
| Supplemental Agreement for work within scope | $508,087 | |
| Supplemental Agreement for work within scope | $1,019,192 | |
| Supplemental Agreement for work within scope | $19,482 | |
| Exercise an Option | $2,301,406 | |
| Original award | $971,302 |
About this award
This is a delivery order under the "Therapeutics Against Infectious Diseases Phase 1" indefinite delivery, indefinite quantity (IDIQ) contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The order, valued at $5,167,891.00, funds a Phase 1 clinical trial unit for therapeutic candidates against infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation that provides research, development, manufacturing, and testing services for biopharmaceutical products targeting infectious diseases. Dynport has been awarded multiple NIAID contracts and IDIQs for preclinical and clinical services related to infectious disease therapeutics and vaccines. This order does not have a set-aside designation. Dynport has subcontracted a portion of the work to IQVIA Government Solutions Inc., a leading provider of healthcare data, analytics, and clinical research services to federal agencies.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Iqvia Government Solutions Inc. | $280,268 |
Quick answers
Who was awarded contract 75N93022F00057?
75N93022F00057 was awarded to Dynport Vaccine Company LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 14, 2021.
How much is contract 75N93022F00057 worth?
The government has obligated $5,167,891 on 75N93022F00057.
Is contract 75N93022F00057 an order under another contract?
Yes. 75N93022F00057 is a delivery order under HHSN272201500005I, an indefinite delivery contract, on Therapeutics Against Infectious Diseases Phase 1.
Was contract 75N93022F00057 competed?
The extent of competition for 75N93022F00057 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award